Martin Babler - Jun 8, 2023 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NLTX)

Role
Director
Signature
/s/ Sean Smith, Attorney-in-Fact for Martin Babler
Stock symbol
NLTX
Transactions as of
Jun 8, 2023
Transactions value $
$0
Form type
4
Date filed
6/9/2023, 04:24 PM
Previous filing
Jun 22, 2022
Next filing
Jun 21, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NLTX Stock Option (Right to Buy) Award $0 +25K $0.00 25K Jun 8, 2023 Common Stock 25K $0.79 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.